In a B-cell lymphoma murine model, Sommermeyer et al. demonstrated that the infusion of CAR-T cells with a 1:1 ratio of CD4+and CD8+ outperformed unselected CAR-T cells as well as CD8+ or CD4+ CAR-T cells alone in terms of anti-tumor effect. This evidence concerns the gene CD8A and B-cell non-Hodgkin lymphoma.